Salix Pharmaceuticals, a maker of gastrointestinal drugs that has been courted by at least four potential suitors over the last year, has finally found a buyer.
Valeant Pharmaceuticals, the acquisitive Canadian pharmaceutical company, has agreed to pay US$10.4 billion for Salix, or US$158 a share in cash. Including debt, the transaction is valued at about US$14.5 billion.
The deal is a turning point for both companies.
For Valeant, which spent the better part of last year unsuccessfully trying to acquire Allergan, the maker of Botox, the acquisition represents a return to form for the company and its chief executive, Michael Pearson.
Valeant is known as an aggressive buyer of smaller drug companies, and failing to secure Allergan, even with the help of hedge fund billionaire William Ackman, was a rare defeat.
And for Salix, which has been courted by Allergan, Actavis and Shire in recent months, the sale to Valeant will put an end to constant deal speculation.
Salix’s share price has risen steadily as speculation of a deal intensified, jumping more than 50 percent in the last three months alone. Sales of the company’s more than 22 drugs, which include Xifaxan, Uceris, Relistor and Apriso, have been growing rapidly. Revenue for this year is expected to exceed US$1.4 billion.
However, Salix, based in Raleigh, North Carolina, has also had trouble with overstocked inventory for its drugs in recent months. Valeant believes it can manage the issues once it owns the company.
By acquiring Salix, Valeant gains another set of products it can plug into its expanding sales pipeline. Valeant is known for acquiring products and expanding their sales, instead of spending billions on research and development in hopes of discovering lucrative new drugs.
Among the deals that have given Valeant a market value of more than US$58 billion was the acquisition of Bausch & Lomb, the eye care company, in 2013 for about US$8.7 billion.
This deal is an unusual turn of events for Valeant. Last year, as Valeant was pressuring Allergan to agree to a deal, Salix nearly played spoiler. Allergan almost acquired Salix late in the summer, a deal that would probably have made Allergan too expensive for Valeant.
However, Allergan never bough Salix, agreeing to sell itself to Actavis for US$66 billion and leaving Valeant on the sidelines during a banner year for healthcare dealmaking.
Salix and Valeant said the combination would lead to cost savings of at least US$500 million within six months, mostly through reducing corporate overhead and research and development spending. They expected the deal to close in the second quarter of this year.
Though some jobs will be in jeopardy at Salix, Valeant said it did not plan any immediate reductions to Salix’s specialty sales force.
Pearson also said Valeant would save money by reducing Salix’s tax rate. Valeant has an effective tax rate of just 4 percent.
In a conference call with analysts and investors scheduled for yesterday morning, Valeant executives will discuss its fourth quarter and full year results and the deal.
Nvidia Corp’s demand for advanced packaging from Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) remains strong though the kind of technology it needs is changing, Nvidia CEO Jensen Huang (黃仁勳) said yesterday, after he was asked whether the company was cutting orders. Nvidia’s most advanced artificial intelligence (AI) chip, Blackwell, consists of multiple chips glued together using a complex chip-on-wafer-on-substrate (CoWoS) advanced packaging technology offered by TSMC, Nvidia’s main contract chipmaker. “As we move into Blackwell, we will use largely CoWoS-L. Of course, we’re still manufacturing Hopper, and Hopper will use CowoS-S. We will also transition the CoWoS-S capacity to CoWos-L,” Huang said
Nvidia Corp CEO Jensen Huang (黃仁勳) is expected to miss the inauguration of US president-elect Donald Trump on Monday, bucking a trend among high-profile US technology leaders. Huang is visiting East Asia this week, as he typically does around the time of the Lunar New Year, a person familiar with the situation said. He has never previously attended a US presidential inauguration, said the person, who asked not to be identified, because the plans have not been announced. That makes Nvidia an exception among the most valuable technology companies, most of which are sending cofounders or CEOs to the event. That includes
TARIFF TRADE-OFF: Machinery exports to China dropped after Beijing ended its tariff reductions in June, while potential new tariffs fueled ‘front-loaded’ orders to the US The nation’s machinery exports to the US amounted to US$7.19 billion last year, surpassing the US$6.86 billion to China to become the largest export destination for the local machinery industry, the Taiwan Association of Machinery Industry (TAMI, 台灣機械公會) said in a report on Jan. 10. It came as some manufacturers brought forward or “front-loaded” US-bound shipments as required by customers ahead of potential tariffs imposed by the new US administration, the association said. During his campaign, US president-elect Donald Trump threatened tariffs of as high as 60 percent on Chinese goods and 10 percent to 20 percent on imports from other countries.
INDUSTRY LEADER: TSMC aims to continue outperforming the industry’s growth and makes 2025 another strong growth year, chairman and CEO C.C. Wei says Taiwan Semiconductor Manufacturing Co (TSMC, 台積電), a major chip supplier to Nvidia Corp and Apple Inc, yesterday said it aims to grow revenue by about 25 percent this year, driven by robust demand for artificial intelligence (AI) chips. That means TSMC would continue to outpace the foundry industry’s 10 percent annual growth this year based on the chipmaker’s estimate. The chipmaker expects revenue from AI-related chips to double this year, extending a three-fold increase last year. The growth would quicken over the next five years at a compound annual growth rate of 45 percent, fueled by strong demand for the high-performance computing
RSS